Skip to main content

Advertisement

Log in

Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management

  • Overactive Bladder (Gopal Badlani, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Lower urinary tract dysfunction can have a significant impact on patients with spinal cord injury. Over the years, many treatment options have become available. This article reviews the assessment and management of neurogenic detrusor overactivity, with a particular focus on articles from the recent literature. Recent guidelines on the subject will be discussed. Management options include antimuscarinics and bladder emptying measures, botulinum toxin A, and neuromodulation in refractory cases and surgery for intractable cases. Recent and relevant publications in these areas will be summarized and discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn. 2006;25(5):441–5.

    Article  PubMed  CAS  Google Scholar 

  2. DeVivo MJ, Chen Y, Mennemeyer ST, Deutsch A. Topics in Spinal Cord Injury Rehabilitation. 2011;16(4):1–9.

    Article  Google Scholar 

  3. Yue Cao YC, Michael J. DeVivo. Topics in Spinal Cord Injury Rehabilitation. 2011;16(4):10–6.

  4. Hackler RH. A 25-year prospective mortality study in the spinal cord injured patient: comparison with the long-term living paraplegic. J Urol. 1977;117(4):486–8.

    PubMed  CAS  Google Scholar 

  5. Lidal IB, Snekkevik H, Aamodt G, Hjeltnes N, Biering-Sorensen F, Stanghelle JK. Mortality after spinal cord injury in Norway. J Rehabil Med. 2007;39(2):145–51.

    Article  PubMed  Google Scholar 

  6. • Abrams P, Agarwal M, Drake M, El-Masri W, Fulford S, Reid S, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int. 2008 Apr;101(8):989–94. This guideline was developed by doctors in the United Kingdom, experts in the urinary tract management of patients with spinal cord injury.

    Article  PubMed  Google Scholar 

  7. • J. Pannek MS, B. Blok, D. Castro-Diaz, G. Del Popolo, G. Kramer, P. Radziszewski, A. Reitz, J-J. Wyndaele. Guidelines on neurogenic lower urinary tract dysfunction. European Association of Urology. 2011. These are current guidelines on the management of various types of neurogenic lower urinary tract dysfunction.

  8. de Groat WC, Yoshimura N. Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. Prog Brain Res. 2006;152:59–84.

    Article  PubMed  Google Scholar 

  9. •• de Groat WC, Yoshimura N. Plasticity in reflex pathways to the lower urinary tract following spinal cord injury. Exp Neurol. May 9. This is an excellent recent review from leaders in their field regarding the neurophysiology of micturition and changes that occur following spinal cord injury.

  10. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453–66.

    Article  PubMed  CAS  Google Scholar 

  11. Wing PC. Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care providers. Who should read it? J Spinal Cord Med. 2008;31(4):360.

    PubMed  Google Scholar 

  12. Watanabe T, Rivas DA, Chancellor MB. Urodynamics of spinal cord injury. Urol Clin North Am. 1996;23(3):459–73.

    Article  PubMed  CAS  Google Scholar 

  13. Kaplan SA, Chancellor MB, Blaivas JG. Bladder and sphincter behavior in patients with spinal cord lesions. J Urol. 1991;146(1):113–7.

    PubMed  CAS  Google Scholar 

  14. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. 1981. J Urol. 2002;167(2 Pt 2):1049–53. discussion 54.

    Article  PubMed  Google Scholar 

  15. Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine (Phila Pa 1976). 2001;26(24 Suppl):129–36.

    Article  Google Scholar 

  16. Wyndaele JJ, Madersbacher H, Kovindha A. Conservative treatment of the neuropathic bladder in spinal cord injured patients. Spinal Cord. 2001;39(6):294–300.

    Article  PubMed  CAS  Google Scholar 

  17. Hansen RB, Biering-Sorensen F, Kristensen JK. Urinary incontinence in spinal cord injured individuals 10–45 years after injury. Spinal Cord. 2010;48(1):27–33.

    Article  PubMed  CAS  Google Scholar 

  18. Hansen RB, Biering-Sorensen F, Kristensen JK. Bladder emptying over a period of 10–45 years after a traumatic spinal cord injury. Spinal Cord. 2004;42(11):631–7.

    Article  PubMed  CAS  Google Scholar 

  19. Bennett CJ, Young MN, Adkins RH, Diaz F. Comparison of bladder management complication outcomes in female spinal cord injury patients. J Urol. 1995;153(5):1458–60.

    Article  PubMed  CAS  Google Scholar 

  20. Cameron AP, Wallner LP, Tate DG, Sarma AV, Rodriguez GM, Clemens JQ. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010;184(1):213–7.

    Article  PubMed  Google Scholar 

  21. Pettersson-Hammerstad K, Jonsson O, Svennung IB, Karlsson AK. Impaired renal function in newly spinal cord injured patients improves in the chronic state–effect of clean intermittent catheterization? J Urol. 2008;180(1):187–91. discussion 91.

    Article  PubMed  Google Scholar 

  22. Vaidyanathan S, Soni BM, Singh G, Oo T, Hughes PL. Barriers to implementing intermittent catheterisation in spinal cord injury patients in Northwest Regional Spinal Injuries Centre, Southport, U.K. ScientificWorldJournal. 2011;11:77–85.

    Article  PubMed  Google Scholar 

  23. Cameron AP, Wallner LP, Forchheimer MB, Clemens JQ, Dunn RL, Rodriguez G, et al. Medical and psychosocial complications associated with method of bladder management after traumatic spinal cord injury. Arch Phys Med Rehabil. 2011;92(3):449–56.

    Article  PubMed  Google Scholar 

  24. Liu CW, Attar KH, Gall A, Shah J, Craggs M. The relationship between bladder management and health-related quality of life in patients with spinal cord injury in the UK. Spinal Cord. 2009;48(4):319–24.

    Article  PubMed  Google Scholar 

  25. Saint S, Elmore JG, Sullivan SD, Emerson SS, Koepsell TD. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. Am J Med. 1998;105(3):236–41.

    Article  PubMed  CAS  Google Scholar 

  26. Desai DG, Liao KS, Cevallos ME, Trautner BW. Silver or nitrofurazone impregnation of urinary catheters has a minimal effect on uropathogen adherence. J Urol. 2010;184(6):2565–71.

    Google Scholar 

  27. Cardenas DD, Moore KN, Dannels-McClure A, Scelza WM, Graves DE, Brooks M, et al. Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury: a prospective, randomized, multicenter trial. PM R. 2011 May;3(5):408–17.

  28. Jahn P, Preuss M, Kernig A, Seifert-Huhmer A, Langer G. Types of indwelling urinary catheters for long-term bladder drainage in adults. Cochrane Database Syst Rev. 2007(3):CD004997.

  29. Ryu KH, Kim YB, Yang SO, Lee JK, Jung TY. Results of urine culture and antimicrobial sensitivity tests according to the voiding method over 10 years in patients with spinal cord injury. Korean J Urol. 2011;52(5):345–9.

    Google Scholar 

  30. Everaert K, Lumen N, Kerckhaert W, Willaert P, van Driel M. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg. 2009;64(4):335–40.

    PubMed  CAS  Google Scholar 

  31. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62.

    Article  PubMed  CAS  Google Scholar 

  32. Bennett N, O’Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol. 2004;171(2 Pt 1):749–51.

    Article  PubMed  CAS  Google Scholar 

  33. O’Leary M, Erickson JR, Smith CP, McDermott C, Horton J, Chancellor MB. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med. 2003;26(2):159–62.

    PubMed  Google Scholar 

  34. • Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert KD. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol. 2008 May;53(5):1021–8. This was a small study assessing combined antimuscarinic therapy in those who failed dose escalation with monotherapy. This approach resulted in successful treatment for 85% of patients.

    Article  PubMed  CAS  Google Scholar 

  35. Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology. 2009;74(4):741–5.

    Article  PubMed  Google Scholar 

  36. Natalin R, Reis LO, Alpendre C, Ikari LY, Prudente A, D’Ancona CA. Triple therapy in refractory detrusor overactivity: a preliminary study. World J Urol. 2010;28(1):79–85.

    Google Scholar 

  37. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100–19.

    Article  PubMed  CAS  Google Scholar 

  38. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41(4):335–40.

    Article  PubMed  CAS  Google Scholar 

  39. • Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200. This article provides evidence for the efficacy of botulinum toxin A in treating NDO from a phase 2 placebo-controlled randomized trial.

    Article  PubMed  CAS  Google Scholar 

  40. Cruz F, Heesakkers J, Aliotta P, Thompson C, Lam W, Daniell G, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. European Urology Supplements. 2011;10(2):190.

    Article  Google Scholar 

  41. Mascarenhas F, Cocuzza M, Gomes CM, Leao N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn. 2008;27(4):311–4.

    Article  PubMed  CAS  Google Scholar 

  42. Del Popolo G, Filocamo MT, Li Marzi V, Macchiarella A, Cecconi F, Lombardi G, et al. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol. 2008;53(5):1013–19.

    Article  PubMed  Google Scholar 

  43. • Dowson C, Khan MS, Dasgupta P, Sahai A. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol. 2010 Dec;7(12):661–7. This review summarizes the efficacy and safety of repeated botulinum toxin injections for NDO.

    Article  PubMed  CAS  Google Scholar 

  44. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–6.

    Article  PubMed  CAS  Google Scholar 

  45. Kessler TM, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol. 2009;113(5):1046–51.

    PubMed  Google Scholar 

  46. Wefer B, Ehlken B, Bremer J, Burgdorfer H, Domurath B, Hampel C, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol. 2010;28(3):385–90.

    Article  PubMed  Google Scholar 

  47. Hori S, Patki P, Attar KH, Ismail S, Vasconcelos JC, Shah PJ. Patients’ perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury. BJU Int. 2009;104(2):216–20.

    Article  PubMed  Google Scholar 

  48. Vastenholt JM, Snoek GJ, Buschman HP, van der Aa HE, Alleman ER, Ijzerman MJ. A 7-year follow-up of sacral anterior root stimulation for bladder control in patients with a spinal cord injury: quality of life and users’ experiences. Spinal Cord. 2003;41(7):397–402.

    Article  PubMed  CAS  Google Scholar 

  49. Van Kerrebroeck PE, Koldewijn EL, Rosier PF, Wijkstra H, Debruyne FM. Results of the treatment of neurogenic bladder dysfunction in spinal cord injury by sacral posterior root rhizotomy and anterior sacral root stimulation. J Urol. 1996;155(4):1378–81.

    Article  PubMed  Google Scholar 

  50. Kutzenberger J, Domurath B, Sauerwein D. Spastic bladder and spinal cord injury: seventeen years of experience with sacral deafferentation and implantation of an anterior root stimulator. Artif Organs. 2005;29(3):239–41.

    Article  PubMed  Google Scholar 

  51. Hohenfellner M, Pannek J, Botel U, Dahms S, Pfitzenmaier J, Fichtner J, et al. Sacral bladder denervation for treatment of detrusor hyperreflexia and autonomic dysreflexia. Urology. 2001;58(1):28–32.

    Article  PubMed  CAS  Google Scholar 

  52. • Martens FM, den Hollander PP, Snoek GJ, Koldewijn EL, van Kerrebroeck PE, Heesakkers JP. Quality of life in complete spinal cord injury patients with a Brindley bladder stimulator compared to a matched control group. Neurourol Urodyn. 2011 Apr;30(4):551–5. This cross-sectional study assessed QoL in patients using SARS compared to a matched controlled group.

    Article  PubMed  Google Scholar 

  53. • Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865–74. This is a systematic review and meta-analysis of the efficacy and safety of neuromodulation for neurogenic lower urinary tract dysfunction, with a nice summary on potential mechanisms of action.

  54. •• Sievert KD, Amend B, Gakis G, Toomey P, Badke A, Kaps HP, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol. 2010 Jan;67(1):74–84. This is a landmark study assessing the use of early neuromodulation during the AD phase of SCI. Results suggest that NDO and DSD can be prevented with this strategy.

    Article  PubMed  Google Scholar 

  55. Game XKT, Elneil S, Hamid R. Neurogenic bladder dysfunction: surgical interventional approaches. Pelvic Organ Dysfunction in Neurological Disease: Cambridge Medicine; 2010, p. 112–26.

  56. Cartwright PC, Snow BW. Bladder autoaugmentation: early clinical experience. J Urol. 1989;142(2 Pt 2):505–8. discussion 20–1.

    PubMed  CAS  Google Scholar 

  57. Stohrer M, Kramer G, Goepel M, Lochner-Ernst D, Kruse D, Rubben H. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. Spinal Cord. 1997;35(7):456–62.

    Article  PubMed  CAS  Google Scholar 

  58. Leng WW, Blalock HJ, Fredriksson WH, English SF, McGuire EJ. Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation. J Urol. 1999;161(3):758–63.

    Article  PubMed  CAS  Google Scholar 

  59. Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int. 2001;88(6):511–25.

    Article  PubMed  CAS  Google Scholar 

  60. Chen JL, Kuo HC. Long-term outcomes of augmentation enterocystoplasty with an ileal segment in patients with spinal cord injury. J Formos Med Assoc. 2009;108(6):475–80.

    Article  PubMed  Google Scholar 

  61. Gerharz EW, Mansson A, Hunt S, Skinner EC, Mansson W. Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol. 2005;174(5):1729–36.

    Article  PubMed  Google Scholar 

  62. Fazili T, Bhat TR, Masood S, Palmer JH, Mufti GR. Fate of the leftover bladder after supravesical urinary diversion for benign disease. J Urol. 2006;176(2):620–1.

    Article  PubMed  Google Scholar 

  63. Cheng JN, Lawrentschuk N, Gyomber D, Rogerson J, Bolton DM. Cystectomy in patients with spinal cord injury: indications and long-term outcomes. J Urol. 2010;184(1):92–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Dr. Arun Sahai and Dr. Prokar Dasgupta acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust. They also acknowledge the support of the MRC Centre for Transplantation.

Dr. Jai Seth, Dr. Jalesh Panicker, Dr. Clare J. Fowler would like to acknowledge UCLH/UCL Institute of Neurology, and received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centre’s funding scheme.

Disclosures

Dr. Arun Sahai has received grants, honoraria (for speaking engagements), and travel expense compensation from Allergan, Ltd. E. Cortes: none; J. Seth: none. Dr. Mohammed Khan has served as an investigator for Allergan, Ltd., receiving grants and travel expense compensation. Dr. Jalesh Panicker has received honoraria (for speaking engagements) from Astellas, and serves on an advisory board to Allergan, Ltd. Dr. Cornelius Kelleher has served as a consultant to Pfizer and Astellas, and has received honoraria and travel expense compensation from those companies. Dr. Thomas Kessler has served as a consultant for Medtronic and Allergan, Ltd. (advisory board). Dr. Clare J. Fowler has served as a consultant to Allergan, Ltd. and Astratech; has provided expert testimony on behalf of Allergan, Ltd.; has received grants from Allergan, Ltd.; and has received honoraria, payment for the development of educational presentations, and travel expense compensation from Allergan, Ltd., Astratech, and Astellas. Dr. Prokar Dasgupta has served as an investigator for Allergan, Ltd. and has received a grant from The Urology Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arun Sahai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sahai, A., Cortes, E., Seth, J. et al. Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management. Curr Urol Rep 12, 404–412 (2011). https://doi.org/10.1007/s11934-011-0221-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-011-0221-1

Keywords

Navigation